

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maxine Jaquet
Date of last notice	1 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	30 May 2023
No. of securities held prior to change	368,017 Ordinary Shares 3,335,611 Options 41,066 Service Rights
Class	HLSAB Performance Rights
Number acquired	371,859
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Issued under the terms of the HLS FY23 Long -Term Incentive Plan approved at the FY22 AGM with performance hurdles to be measured over a three-year period commencing 1 July 2022.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p>	<p>368,017 Ordinary Shares</p> <p>3,335,611 Options</p> <p>41,066 Service Rights</p> <p>371,859 Performance Rights</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issued under the terms of the HLS FY23 Long -Term Incentive Plan approved at the FY22 AGM with performance hurdles to be measured over a three-year period commencing from 1 July 2022.</p>

Part 2 – Change of director's interests in contracts Not applicable

Part 3 – +Closed period

<p>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</p>	<p>N/A</p>
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	<p>N/A</p>
<p>If prior written clearance was provided, on what date was this provided?</p>	<p>N/A</p>

Authorised by the Company Secretary.

Mary Weaver
 Company Secretary
 Date: 1 June 2023

+ See chapter 19 for defined terms.